How should a female patient of reproductive age with borderline personality disorder, taking Zoloft (sertraline) and Lamictal (lamotrigine), be managed when experiencing mood instability exacerbated by her menstrual cycle?

Management of Menstrual-Related Mood Instability in BPD

For a patient with borderline personality disorder on sertraline and lamotrigine experiencing menstrual-related mood instability, consider perimenstrual preventive treatment with NSAIDs (such as naproxen for 5 days starting 2 days before menses) or evaluate continuous combined hormonal contraceptives if she does not have migraine with aura. 1

Understanding the Clinical Context

Your patient is describing premenstrual dysphoric disorder (PMDD)-like symptoms superimposed on borderline personality disorder. This is a clinically important distinction because:

• Sertraline is FDA-approved for PMDD and can be dosed either daily throughout the menstrual cycle or limited to the luteal phase 2
• The current regimen may need optimization rather than complete overhaul, given that both medications address different symptom domains 3, 4

Optimizing Current Sertraline Therapy

First, consider adjusting the sertraline dosing strategy specifically for menstrual-related symptoms:

• Increase sertraline to 50-150 mg/day if not already at therapeutic dose for PMDD 2
• Consider luteal phase dosing (starting 14 days before expected menses through the first full day of menses) if daily dosing hasn't been tried 2
• If switching to luteal phase dosing at 100 mg/day, use a 50 mg/day titration step for 3 days at the beginning of each luteal phase period 2

The evidence shows sertraline improves quality of life across multiple domains including work, social functioning, and concentration in patients with depression, though specific PMDD efficacy data beyond 3 menstrual cycles is limited 5, 2

Role of Lamotrigine in BPD

Lamotrigine's evidence for BPD is mixed and should temper expectations:

• Early open-label studies showed dramatic improvements in affective instability, with patients moving from severe impairment (GAF 40s) to high functioning (GAF 80s) on 75-300 mg/day 4
• However, a large 2018 randomized controlled trial found no benefit of lamotrigine over placebo for BPD symptoms at 52 weeks, with low adherence rates in both groups 6
• A retrospective case series showed improvement in affective instability at doses of 50-200 mg/day, but this was uncontrolled 3

Despite limited evidence, continuing lamotrigine is reasonable if the patient has shown some benefit, as mood stabilizers may help the affective dysregulation component of BPD 7

Hormonal Interventions for Menstrual-Related Symptoms

Perimenstrual preventive treatment should be strongly considered:

• Long-acting NSAIDs (naproxen) taken daily for 5 days, beginning 2 days before expected menstruation 1
• Continuous combined hormonal contraceptives (without hormone-free intervals) can benefit women with pure menstrual-related symptoms 1
• Critical contraindication: Combined hormonal contraceptives are absolutely contraindicated if the patient has migraine with aura due to increased stroke risk 1

Practical Management Algorithm

Step 1: Optimize sertraline for PMDD

• Ensure dose is 50-150 mg/day 2
• Consider luteal phase dosing if not tried 2
• Reassess after 2-3 menstrual cycles 2

Step 2: Add perimenstrual NSAID prophylaxis

• Naproxen for 5 days starting 2 days before menses 1
• This addresses the inflammatory component of menstrual symptoms

Step 3: Evaluate hormonal contraception

• Screen for migraine with aura (absolute contraindication) 1
• If appropriate, consider continuous combined hormonal contraceptives 1

Step 4: Continue lamotrigine if tolerated

• Despite negative RCT data, individual response may vary 6
• Monitor for rash and titrate slowly 3, 4

Important Caveats

Polypharmacy concerns: Over 75% of BPD patients take psychotropic medications, but no drugs are licensed specifically for BPD 6, 8. The goal should be targeted symptom management rather than adding medications indiscriminately 8, 7.

Adherence monitoring: The 2018 lamotrigine RCT showed only 36% of patients were still taking medication at 52 weeks, highlighting the importance of addressing adherence barriers 6.

Cardiac considerations: Sertraline has a favorable cardiac profile compared to other antidepressants, with lower risk of QT prolongation 9. This is relevant given the high rates of impulsivity and potential overdose risk in BPD 9.

Psychotherapy remains essential: Dialectical behavior therapy (DBT) has strong evidence for reducing self-harm and suicidal behavior in BPD, and medication should complement rather than replace evidence-based psychotherapy 10.